In today’s health climate, helping patients maintain health and wellness has never been more important. Part of that support is providing care that will mitigate or altogether avoid the consequences associated with exposure to opioids as a part of health care treatments.
A new FDA-approved treatment called EXPAREL aims to manage postsurgical pain in certain oral, jaw and face surgeries with significantly less opioid use. EXPAREL is a non-opioid local analgesic for children ages six and older. It works by numbing or reducing sensation in specific parts of the body, providing long-lasting pain management when patients need it most. To learn more, view this article: https://www.exparel.com/hcp/specialty/oral-maxillofacial
D9613 is defined by the CDT© American Dental Association as “Infiltration of sustained release therapeutic drug – per quadrant.” For the complete definition of D9613, see the 2024 CDT American Dental Association.
For more information about how to submit claims and benefit information for D9613, please download the pdf 2024 GEHA Plan Manual for Dental Providers. The manual also describes all covered dental benefits for GEHA health and dental benefits members. You can find this manual by visiting the Connection Dental Resource Center.
The information contained herein is for informational and educational purposes only. This information is not a substitute for professional medical advice and if you have questions regarding a medical condition, regimen or treatment you should always seek the advice of a qualified health care provider. Never disregard or delay seeking medical advice from a qualified medical professional because of information you have read herein.